Mounjaro (Tirzepatide) is a once-weekly injectable medication for type 2 diabetes that uniquely targets both GLP-1 and GIP receptors to improve blood sugar control and support weight loss. It helps regulate insulin secretion, slows gastric emptying, reduces appetite, and may offer cardiovascular benefits. Clinical studies show significant HbA1c reduction and an average weight loss of 12–15%. Common side effects include nausea, vomiting, and gastrointestinal discomfort. Mounjaro is not for type 1 diabetes and should be used under medical supervision.
